Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Immunohistopathologically documented relapsed or refractory CD20+ indolent lymphomas or mantle cell lymphoma
• •* Indolent B-cell lymphomas including any of the following subtypes:
• •* Follicular lymphoma (grade I, II, or III)
• •* Small lymphocytic lymphoma or chronic lymphocytic leukemia
• •* Marginal zone lymphoma (splenic, nodal, and extra-nodal)
• •* Lymphoplasmacytoid lymphoma
• •Ineligible for or unwilling to participate in other FHCRC/UWMC protocols
• •Serological evidence of prior exposure to Epstein-Barr virus
• •Must agree to undergo peripheral blood drawing, bone marrow biopsy, lymph node biopsy, and nuclear medicine imaging
• •Must agree to cytoreductive chemotherapy if necessary to reduce lymph nodes to \< 5 cm in diameter or circulating B lymphocyte counts to \< 5,000/mm\^3
• •No pulmonary involvement
• •No CNS involvement
• •PATIENT CHARACTERISTICS:
• •Age:
• •Any age
• •Performance status:
• •Not specified
• •Life expectancy:
• •At least 90 days
• •Hematopoietic:
• •Not specified
• •Hepatic:
• •No active hepatitis B infection
• •Renal:
• •Not specified
• •Other:
• •No HIV positivity
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No history of hypersensitivity reactions to murine proteins
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 4 months since prior rituximab, tositumomab, or ibritumomab
• •No prior allogeneic stem cell transplantation
• •No other concurrent immunotherapy (e.g., interferons, vaccines, or other cellular products)
• •Chemotherapy:
• •At least 2 years since prior fludarabine or cladribine
• •At least 4 weeks since prior chemotherapy and recovered
• •Endocrine therapy:
• •No concurrent systemic corticosteroids except to treat toxicity from chemotherapy or cellular immunotherapy
• •Radiotherapy:
• •Not specified
• •Surgery:
• •Not specified
• •Other:
• •At least 4 weeks since prior immunosuppressive therapy and recovered
• •No concurrent pentoxifylline
• •No other concurrent investigational agents